Citeline Podcasts

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.

https://scrip.citeline.com/SC149072/Quick-Listen-Scrips-Five-MustKnow-Things

Pink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron’s deal with the US government to develop a COVID-19 monoclonal antibody (:34), US FDA Commissioner Robert Califf hiring a new senior advisor (12:10), and optimizing dosing in cancer combination therapies (21:21).

More On These Topics From The Pink Sheet

Price Caps In Regeneron’s COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie: https://pink.citeline.com/PS148843/Price-Caps-In-Regenerons-COVID-Monoclonal-Deal-With-HHS-Not-A-Precedent-But-Enough-For-Bernie

Califf Hires New US FDA Senior Advisor, But Duties Seem Vague: https://pink.citeline.com/PS148848/Califf-Hires-New-US-FDA-Senior-Advisor-But-Duties-Seem-Vague

Project Optimus Is Coming To Cancer Combination Therapy Development: https://pink.citeline.com/PS148841/Project-Optimus-Is-Coming-To-Cancer-Combination-Therapy-Development

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.

https://scrip.citeline.com/SC149038/Quick-Listen-Scrips-Five-MustKnow-Things

In the second part of HBW Insight’s exclusive interview with OTC industry veteran Birgit Schuhbauer, we discuss the trends that will shape the future of consumer health. Drawing on her extensive experience in consumer health, most recently as global vice president of J&J’s Self Care franchise and president of the AESGP,Schuhbauer gives her views on: consumer shifts towards self-care and prevention, digitalisation and e-commerce, supply chain resilience and sustainability. Schuhbauer also gives an insider perspective on moves by companies like Kenvue and Haleon to spin out as independent OTC players, and the implications for Rx-to-OTC switch, for example.

어동규 대웅이노베이션홀딩스 대표의 Scrip Intelligence 인터뷰 기사를 요약한 내용입니다

https://scrip.citeline.com/SC148741/Know-The-Enemy-And-Know-Yourself-Before-Entering-US-Daewoong-Exec-Advises

Pink Sheet reporter and editors discuss the US Federal Trade Commission ending its attempt to block the Amgen acquisition of Horizon Therapeutics (:28), a proposed public-private partnership to develop ultra-rare cancer drugs (9:54), and a slow-down in ANDA submissions to the US Food and Drug Administration (22:02).

More On These Topics From The Pink Sheet

FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement: https://pink.citeline.com/PS148804/FTCs-Test-Case-Opposing-Amgen-Horizon-Deal-Ends-With-No-Bundling-Agreement

Ultra-Rare Tumors: Public-Private Partnership Eyed To Boost Drug Development: https://pink.citeline.com/PS148813/Ultra-Rare-Tumors-Public-Private-Partnership-Eyed-To-Boost-Drug-Development

ANDA Submissions Lagging As FY 2023 Nears Its End: https://pink.citeline.com/PS148818/ANDA-Submissions-Lagging-As-FY-2023-Nears-Its-End

In this episode, Medtech Insight regulatory reporter Hannah Daniel and managing editor Amanda Maxwell speak to Marcel Gehrung, co-founder and CEO of Cyted. We talk to Marcel about global regulations for Cyted’s product Endosign, and how his company chose to leverage the product’s flexibility to gain approval and reach markets as efficiently as possible. We also talk about different market authorization requirements in the EU, UK, and US, and the use of AI in healthcare spaces in the UK.

Dr Reddy's Laboratories' co-chairman and managing director, G V Prasad, talks with Scrip’s Anju Ghangurde about his conversations with late founder Dr Anji Reddy, the company’s “Horizon 2” trajectory, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession issues and his new book.

https://scrip.citeline.com/SC149008/Dr-Reddys-MD-On-The-Next-Horizon-OwnerManaged-Firms-Birds-And-Beliefs

In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.